ELV

Elevance Health

ELV

Attention (50-day avg)0.01%

Attention rank (50-day avg)#467

Bullish sentiment (50-day avg)79%

Price to earnings ratio17.4

Market capitalization85.6B

Earnings per share22.6

Dividend yield (TTM)1.74%

Revenue (annual)199.1B

Net income (annual)5.7B

Social

What share of all stock conversation is about ELV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% -0.01	0.01% -0.02

Jul 16

Elevance Health (ELV) reported Q2 2026 earnings, beating adjusted EPS estimates of $6.18 with $7.45, and raised full-year adjusted EPS guidance to at least $27.00, but the stock fell due to concerns over rising medical costs and a surging medical loss ratio.
The company's CEO has been under criticism, with some analysts suggesting that a change in leadership could be beneficial, while others point to the company's past Medicare fraud as a reason to be cautious.
Despite the recent decline, the stock is considered a "cyclical trough" with a fair value of around $390, and some analysts see a potential upside of around 17% if medical costs peak, making it a contrarian value play.

Generated by AI

Sentiment

Of the messages about ELV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	63.51% -34.35	65.31% -26.54
Bearish	—	0% 0	36.49% +34.35	34.69% +26.54

Bullish· Jan 28

The company's Q4 and FY2025 results were strong, with revenue and EPS beating expectations, and guidance for FY2026 was raised.
The company's managed care segment, Carelon, is scaling fast, with a 33% YoY increase to $18.3B in Q3 2025, and is shifting the mix toward services.
With low institutional ownership (~3%), there's plenty of room for upside as funds start to increase exposure, and improving fundamentals and growing contracts are expected to push the price higher.

Bearish· Jan 28

Elevance Health Inc. ($ELV) missed analyst consensus by -6% with its reduced guidance for 2026, citing persistent high medical costs.
The company's earnings report showed a decline in production and constrained supply, leading to a decrease in revenue and profits.
$ELV's stock price has dropped significantly, with some analysts predicting a 22% decline in the next 2-3 weeks to around $250.

Generated by AI

Topics

Of the messages about ELV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	28.49%	14.14%
Macro	—	—	20.11%	30.5%
Earnings	—	—	12.57%	13.36%
Technical Analysis	—	—	15.36%	11.73%
Controversies	—	—	3.35%	0.39%
Analysts	—	—	20.11%	29.89%

Earnings· Jul 15

Elevance Health (ELV) reported Q2 2026 earnings that beat estimates, with adjusted EPS of $7.45 vs. $6.21 forecast and revenue of $49.8B vs. $48.63B expected.
The company raised its 2026 adjusted EPS guidance to at least $27.00 and operating cash flow guidance to $6.0 billion, despite a YoY EPS dip of 15.72%.
Elevance Health's Q2 2026 results highlighted resilient growth, solid execution, and continued strength in its healthcare business, but worries about margins weighed on the stock, with a 7% drop in share price.

Announcements· Jan 28

Elevance Health Inc. reported Q4 2025 operating revenue of $49.3 billion, a 10% increase year-over-year, and full-year revenue of $197.6 billion, a 13% rise.
The company's Q4 2025 diluted EPS was $2.47, while adjusted diluted EPS was $3.33, meeting expectations.
Elevance Health plans to allocate $2.3 billion to share buyback in 2026, as highlighted in its fourth-quarter earnings call.

Generated by AI

Community

Of the messages about ELV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80.65%	74.6%	49.53%
Newcomers	100%	19.35%	25.4%	50.47%

Regulars· Apr 7

The lithium market is experiencing a supply shortage due to China's refineries locking in ore 1-2 months ahead.
Traders' stocks are at multi-week lows, contributing to a narrowing supply of lithium.
A surge in lithium prices appears inevitable, with spodumene prices being a key factor.

Newcomers· Feb 24

Many newcomers are focused on the company's performance and potential catalysts, with some highlighting strong operating performance and others mentioning potential catalysts later in 2026.
Some newcomers are comparing Elevance Health to other companies, such as UnitedHealth (UNH) and Cigna, and suggesting that these alternatives may be better options.
Newcomers are also discussing the stock's price movement and potential trading opportunities, including a mention of a 10% potential upside and a suggested scale-in and scale-out range for options trading.

Generated by AI

Elevance Health has delivered a 1 year gain that puts the stock firmly on investors' radar, and the latest reaffirmed earnings outlook has only sharpened the focus on what you are paying for each dollar of profit. With the price around US$410.95 at the last close, the key issue now is whether that tag lines up with the insurer's earnings power. The stock is up 33.6% over the past year, which raises the question of whether that move is grounded in its underlying earnings profile. Management...

10d agoYahoo Finance

Elevance Health Inc. stock underperforms Wednesday when compared to competitors

13d agoMarketWatch

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.

13d agoYahoo Finance

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Detailed price information for Elevance Health Inc (ELV-N) from The Globe and Mail including charting and trades.

14d agoThe Globe and Mail

Elevance leads UBS health benefits survey as employers brace for higher costs (ELV:NYSE)

UBS benefits survey ranks Elevance top insurer as 77% of employers rebid 2027 plans; GLP-1 costs surge and big PBMs stay strong—read now.

16d agoSeeking Alpha

Up 36% in the Last 12 Months, Does Elevance Health Stock Have More Room to Run Through 2028?

Key Takeaways:Guidance Raised: Elevance Health lifted 2026 adjusted EPS guidance to at least $27, up from prior levels, after a strong Q2. Price Projection: Based on current execution, ELV stock could reach $494 by December 2028.

18d agoYahoo Finance

Also Discussed

Investors talking about ELV also mention

#	Name	Attention
1	Centene CorpCNC	0%0
2	Molina Healthcare Inc.MOH	0%new
3	The Cigna GroupCI	0%0
4	Humana Inc.HUM	0%+0
5	UnitedHealth Group IncorporatedUNH	0%-0.02
6	Alignment Healthcare, Inc.ALHC	0%0
7	HCA Healthcare Inc.HCA	0%0
8	CVS Health CorporationCVS	0%0
9	Oscar Health, Inc.OSCR	0.05%+0.02
10	The Travelers Companies, Inc.TRV	0%new

Elevance Health, Inc.

Healthcare
Healthcare Plans

Elevance Health, Inc. is a diversified health company headquartered in Indianapolis, Indiana. The company focuses on supporting health at every life stage by integrating medical, pharmacy, behavioral, and complex-care services. Elevance Health operates through several key segments. Its Health Benefits segment provides a broad range of commercial, Medicaid, Medicare, and specialty health plans to individuals, employers, and government programs. Through CarelonRx, it offers pharmacy benefit management solutions, including prescription management and related pharmacy services. Carelon Services delivers care management, analytics, and other clinical and administrative services aimed at coordinating and improving care quality. Together, these businesses enable Elevance Health to serve as a major player in the U.S. healthcare system, connecting health plans, care providers, and consumers to streamline access to care and support better health outcomes across diverse populations.

Website

Location

220 Virginia Avenue

Indianapolis, IN, 46204

United States

Social

What share of all stock conversation is about ELV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% -0.01	0.01% -0.02

Jul 16

Elevance Health (ELV) reported Q2 2026 earnings, beating adjusted EPS estimates of $6.18 with $7.45, and raised full-year adjusted EPS guidance to at least $27.00, but the stock fell due to concerns over rising medical costs and a surging medical loss ratio.
The company's CEO has been under criticism, with some analysts suggesting that a change in leadership could be beneficial, while others point to the company's past Medicare fraud as a reason to be cautious.
Despite the recent decline, the stock is considered a "cyclical trough" with a fair value of around $390, and some analysts see a potential upside of around 17% if medical costs peak, making it a contrarian value play.

Generated by AI

Sentiment

Of the messages about ELV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	63.51% -34.35	65.31% -26.54
Bearish	—	0% 0	36.49% +34.35	34.69% +26.54

Bullish· Jan 28

The company's Q4 and FY2025 results were strong, with revenue and EPS beating expectations, and guidance for FY2026 was raised.
The company's managed care segment, Carelon, is scaling fast, with a 33% YoY increase to $18.3B in Q3 2025, and is shifting the mix toward services.
With low institutional ownership (~3%), there's plenty of room for upside as funds start to increase exposure, and improving fundamentals and growing contracts are expected to push the price higher.

Bearish· Jan 28

Elevance Health Inc. ($ELV) missed analyst consensus by -6% with its reduced guidance for 2026, citing persistent high medical costs.
The company's earnings report showed a decline in production and constrained supply, leading to a decrease in revenue and profits.
$ELV's stock price has dropped significantly, with some analysts predicting a 22% decline in the next 2-3 weeks to around $250.

Generated by AI

Topics

Of the messages about ELV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	28.49%	14.14%
Macro	—	—	20.11%	30.5%
Earnings	—	—	12.57%	13.36%
Technical Analysis	—	—	15.36%	11.73%
Controversies	—	—	3.35%	0.39%
Analysts	—	—	20.11%	29.89%

Earnings· Jul 15

Elevance Health (ELV) reported Q2 2026 earnings that beat estimates, with adjusted EPS of $7.45 vs. $6.21 forecast and revenue of $49.8B vs. $48.63B expected.
The company raised its 2026 adjusted EPS guidance to at least $27.00 and operating cash flow guidance to $6.0 billion, despite a YoY EPS dip of 15.72%.
Elevance Health's Q2 2026 results highlighted resilient growth, solid execution, and continued strength in its healthcare business, but worries about margins weighed on the stock, with a 7% drop in share price.

Announcements· Jan 28

Elevance Health Inc. reported Q4 2025 operating revenue of $49.3 billion, a 10% increase year-over-year, and full-year revenue of $197.6 billion, a 13% rise.
The company's Q4 2025 diluted EPS was $2.47, while adjusted diluted EPS was $3.33, meeting expectations.
Elevance Health plans to allocate $2.3 billion to share buyback in 2026, as highlighted in its fourth-quarter earnings call.

Generated by AI

Community

Of the messages about ELV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	80.65%	74.6%	49.53%
Newcomers	100%	19.35%	25.4%	50.47%

Regulars· Apr 7

The lithium market is experiencing a supply shortage due to China's refineries locking in ore 1-2 months ahead.
Traders' stocks are at multi-week lows, contributing to a narrowing supply of lithium.
A surge in lithium prices appears inevitable, with spodumene prices being a key factor.

Newcomers· Feb 24

Many newcomers are focused on the company's performance and potential catalysts, with some highlighting strong operating performance and others mentioning potential catalysts later in 2026.
Some newcomers are comparing Elevance Health to other companies, such as UnitedHealth (UNH) and Cigna, and suggesting that these alternatives may be better options.
Newcomers are also discussing the stock's price movement and potential trading opportunities, including a mention of a 10% potential upside and a suggested scale-in and scale-out range for options trading.

Generated by AI

Elevance Health

Social

Jul 16

Bullish· Jan 28

Bearish· Jan 28

Earnings· Jul 15

Announcements· Jan 28

Regulars· Apr 7

Newcomers· Feb 24

Elevance Health (ELV) Stock May Be Below Fair Value As Guidance Was Reaffirmed

Elevance Health Inc. stock underperforms Wednesday when compared to competitors

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Elevance leads UBS health benefits survey as employers brace for higher costs (ELV:NYSE)

Up 36% in the Last 12 Months, Does Elevance Health Stock Have More Room to Run Through 2028?

Also Discussed

Elevance Health, Inc.

Company Information

Location

Elevance Health (ELV) Stock May Be Below Fair Value As Guidance Was Reaffirmed

Elevance Health Inc. stock underperforms Wednesday when compared to competitors

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Wells Fargo Reaffirms Their Buy Rating on Elevance Health (ELV)

Elevance leads UBS health benefits survey as employers brace for higher costs (ELV:NYSE)

Up 36% in the Last 12 Months, Does Elevance Health Stock Have More Room to Run Through 2028?

Also Discussed

Social

Jul 16

Bullish· Jan 28

Bearish· Jan 28

Earnings· Jul 15

Announcements· Jan 28

Regulars· Apr 7

Newcomers· Feb 24